FDA approves Merck RSV shot for infants, competing with Sanofi and AstraZeneca, reducing hospitalizations

From CNBC: 2025-06-09 15:32:00

The FDA approved Merck’s Enflonsia shot to protect infants from respiratory syncytial virus, competing with Sanofi and AstraZeneca’s Beyfortus. Merck expects orders to start in July before RSV season. Doctors gain new treatment option to reduce virus deaths and hospitalizations. Merck’s shot reduces RSV-related hospitalizations by over 84%.

Sanofi plans to increase Beyfortus supply after high demand in 2023. Merck’s Enflonsia can be given to infants regardless of weight, offering dosing convenience. FDA paused RSV vaccine testing in young children for safety concerns. Vaccine advisors will meet in June to make recommendations on RSV shots and other immunizations.



Read more at CNBC: FDA approves Merck RSV shot for infants to rival Sanofi AstraZeneca